Revenue: As of FY2026 Q2, the actual value is USD 0.

EPS: As of FY2026 Q2, the actual value is USD -0.49, missing the estimate of USD -0.26.

EBIT: As of FY2026 Q2, the actual value is USD -4.297 M.

The provided Form 8-K for Edesa Biotech, Inc. announces the issuance of a press release on May 14, 2026, detailing financial results for the three and six months ended March 31, 2026 . However, the actual financial results, operational metrics, or any forward-looking guidance are not included within the text of this Form 8-K itself . Therefore, no specific financial or operational metrics can be extracted from the provided reference .